Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna

Moderna unveiled promising results for its personalized cancer vaccine on Tuesday. The results could spark downtrodden Moderna stock.

Why Merck's $250 Million Investment In Moderna May Have Just Paid Off

mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRUDA monotherapy in stage III/IV melanoma patients with high risk of recurrence following complete resection Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial Companies plan to discuss results with regulatory authorities and initiate a Phase 3 study in melanoma in 2023 and rapidly expand to additional tumor types CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / December 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival (RFS) versus KEYTRUDA alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection. Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.31-1.08]; one-sided p-value=0.0266) compared with KEYTRUDA alone.

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial

ALEXANDRIA, Va.--( BUSINESS WIRE )--TransVoyant, the world's only global intelligent supply chain execution platform, announced it has closed its first strategic growth equity financing co-led by Merck Global Health Innovation Fund (MGHIF) and P74 Ventures, bringing the company's total funding to more than $30 million.

Merck Global Health Innovation Fund and P74 Ventures Make Strategic Investment in TransVoyant for Intelligent, ‘Self Aware' Supply Chain Platform

McKesson

Vertex Pharmaceuticals

Though energy companies have been among the best-performing stocks in the S&P 500 index, here we discuss some top-performing non-energy S&P 500 stocks like MRK, VRTX and MCK.

3 Non-Energy S&P 500 Stocks With Enough Energy to Boost Returns

Imago Biosciences

RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago BioSciences, Inc. (Nasdaq: IMGO). On Nov. 21, 2022, Merck announced that it had entered into a definitive agreement to acquire Imago.

Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.

Celsius Holdings

Clearfield

Dow Inc

Enphase Energy

Futu Holdings

Honeywell

McDonald's

Brigham Minerals

NIKE

Northern Oil and Gas

Nuvalent

AiHuiShou International Co Ltd

SPDR S&P 500 ETF Trust

TAL Education Group

Tidewater

Visa

Viridian Therapeutics

Verizon

Zymeworks Inc

Zynex Inc

Two new Breakout Stocks for Week 50 with better than 10% short-term upside potential and one Dow 30 Pick. Average cumulative returns now up to +131.5% YTD. This week 1 of 4 high frequency breakout picks gained over 10% in less than a week with peak gains in VITL +10.4% while PBT hit +6.22% and CPRX +4.4%.

MDA Breakout Stocks Week 50 - December 2022: Short-Term Picks To Give You An Edge

Axsome Therapeutics

These stocks' tailwinds should continue blowing in the new year.

3 High-Flying Stocks in 2022 That Should Keep Soaring in 2023

Bristol-Myers

Deere & Company

Today's Research Daily features update on the Q4 earnings season and new research reports on Merck (MRK), Bristol-Myers (BMY) and Deere (DE).

Early Q4 Earnings Results and Analyst Reports for Merck, Bristol-Myers & Deere

Does Merck (MRK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Merck (MRK) Is Up 2.36% in One Week: What You Should Know

Agree Realty

Chubb

ConocoPhillips

Dollar General

Dollar Tree

Heartland Express

MSC Industrial Direct

nVent Electric plc

Oracle

Procter & Gamble

U.S. Bancorp

Walmart

Value-oriented investors have done better than growth managers overall at investing this year. A top value fund manager explains his stock picks.

Patience Pumps Up Hot American Century Fund's Stock Picks

Archer-Daniels-Midland Company

Hershey

UnitedHealth Group

Amid the rising possibility of a recession, defensive stocks with solid prospects will cushion investors from market jitters while their robust fundamentals ensure higher returns. ADM, HSY, UNH and MRK are some such stocks.

4 Defensive Stocks to Prepare Your Portfolio for a Recession

Chevron

General Mills

Is it too late to buy these soaring stocks?

3 High-Yielding Stocks That Are Up 27%-Plus This Year

Is Merck stock a buy after the company announced its acquisition of Imago, a bone marrow diseases company? Is MRK stock a buy now?

Is Merck Stock A Buy After Surging To A Fresh High On Its Imago Buyout Plans?

Medtronic

Suncor Energy

Exxon Mobil

As the SPX has risen to 4,000, some stocks have become outrageously expensive. Others, in the same sector, are still very cheap.

2 Urgent Dividend Sells And 2 Blue Chip Replacements To Increase Your Income

J. M. Smucker

During times of heightened volatility, adding low-beta stocks can help blend in an extra layer of portfolio defense.

Should Investors Consider These 3 Low-Beta Stocks?

Caterpillar

We have narrowed our search to four Dow stocks. These are: CAT, WMT, MRK, UNH.

Top 4 Blue-Chip Stocks to Enhance Your Portfolio in December

Wells Fargo

Wondering how to invest in stocks and mutual funds amid a grim market? Red-hot Invesco Comstock Select Fund is doubling down on its strategy.

Hot Fund To SEC: We're Boosting Bets On Best Stock Picks

Merck & Co., Inc. (NYSE:MRK ) 2022 5th Annual Evercore ISI HealthCONx Conference Call December 1, 2022 9:40 AM ET Company Participants Peter Dannenbaum - Vice President of Investor Relations Eliav Barr - Chief Medical Officer & Head of Global Clinical Development of Merck Research Laboratories Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Hello, everyone. Thank you for joining us.

Merck & Co., Inc. (MRK) 2022 5th Annual Evercore ISI HealthCONx Conference (Transcript)

Merck (MRK) could produce exceptional returns because of its solid growth attributes.

3 Reasons Growth Investors Will Love Merck (MRK)

RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from clinical trials and real-world studies at the upcoming 64th American Society of Hematology (ASH) Annual Meeting from Dec. 10-13, 2022, in New Orleans, Louisiana and virtually. New and updated data for KEYTRUDA, Merck's anti-PD-1 therapy, as well as from the company's investigational medicines favezelimab (anti-LAG-3 antibody), zilovertamab vedotin (antibody-drug conjugate targeting receptor tyrosine kinase-like orphan receptor 1 [ROR1]), and nemtabrutinib (reversible, non-covalent Bruton's tyrosine kinase [BTK] inhibitor) will be featured in nearly 40 abstracts.

Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting

AbbVie

Edwards Lifesciences

Intuitive Surgical

Johnson & Johnson

Eli Lilly

Amid rising concerns about the state of the global economy, rising inflation, central bank interest rate hikes and increased Covid-19 restrictions in China, marked indexes were mixed on Wednesday morning.

Gurus Prescribed These Health Care Stocks in the 3rd Quarter

News for Merck Stock (MRK)